Atlas Trials

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Clinical trial NCT04824092 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04824092
Sponsor
Incyte Corporation
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma
Start date
2021-05-11
Primary completion
2026-09-01
Enrollment
899

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.